SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Balch CM,Buzaid AC,Soong S-J,Atkins MB,Cascinelli N,Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 36353648.
  • 2
    Balch CM,Soong S-J,Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol. 2001; 19: 36223634.
  • 3
    Agarwala SS,Kirkwood JM. Update on adjuvant interferon therapy for high-risk melanoma. Oncology (Williston Park). 2002; 16: 11771187; discussion 1190–1192, 1197.
  • 4
    Kirkwood JM,Strawderman MH,Ernstoff MS,Smith TJ,Borden EC,Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14: 717.
  • 5
    Kirkwood JM,Ibrahim JG,Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of Intergroup Trial E1690/S9111/C9190. J Clin Oncol. 2000; 18: 24442458.
  • 6
    Kirkwood JM,Ibrahim JG,Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup Trial E1694/S9512/C509801. J Clin Oncol. 2001; 19: 23702380.
  • 7
    Wheatley K,Ives N,Hancock B,Gore M,Eggermont A,Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003; 29: 241252.
  • 8
    Wheatley K,Ives N,Eggermont J, et al. Interferon-α as adjuvant therapy for melanoma: an individual patient meta-analysis of randomized trials. J Clin Oncol. 2007; 25(18S): 478s. Abstract 8526.
  • 9
    Borden EC,Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-alpha. Semin Oncol. 1998; 25(1 suppl 1 ): 38.
  • 10
    Sondak VK,Flaherty LE. Adjuvant high-dose interferon revisited. Cancer J. 2000; 6: 132134.
  • 11
    Gogas H.Dafni U,Bafaloukos D, et al. A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma. J Clin Oncol. 2007; 25(18S): 473s. Abstract 8505.
  • 12
    Kirkwood JM,Bender C,Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002; 20: 37033718.
  • 13
    Malik UR,Makower DF,Wadler S. Interferon-mediated fatigue. Cancer. 2001; 92(6 suppl ): 16641668.
  • 14
    Miller RL,Steis RG,Clark JW, et al. Randomized trial of recombinant α2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res. 1989; 49: 18711876.
  • 15
    van Londen GJ,Mascarenhas B,Kirkwood JM. Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI [letter]. J Clin Oncol. 2001; 19: 3794.
  • 16
    Jonasch E,Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001; 6: 3455.
  • 17
    Trask PC,Paterson AG,Esper P,Pau J,Redman B. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology. 2004; 13: 526536.
  • 18
    Levesque N,Mitchinson K,Lawrie D, et al. Benefits of hydration in patients receiving intron A therapy for high-risk melanoma: a nursing support program to minimize drug-related side effects. Melanoma Res. 2006; 16: S38S39.
  • 19
    Drapkin R,Barolo JL,Blower PR. Effect of granisetron on performance status during high-dose interferon therapy. Oncology. 1999; 57: 303305.
  • 20
    Hauser P. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. Gastroenterol Clin North Am. 2004; 33(1 suppl ): S35S50.
  • 21
    Lerner DM,Stoudemire A,Rosenstein DL. Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics. 1999; 40: 428435.
  • 22
    Malek-Ahmadi P. Mood disorders associated with interferon treatment: theoretical and practical considerations. Ann Pharmacother. 2001; 35: 489495.
  • 23
    Nishihori T,Abdo-Matkiwsky M,Fleishman SB,Blum RH. Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma. Am J Clin Oncol. 2005; 28: 526526.
  • 24
    Greenberg DB,Jonasch E,Gadd MA, et al. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer. 2000; 89: 356362.
  • 25
    Caraceni A,Gangeri L,Martini C, et al. Neurotoxicity of interferon-α in melanoma therapy: results from a randomized controlled trial. Cancer. 1998; 83: 482489.
  • 26
    Morgan JC,Sethi KD. Drug-induced tremors. Lancet Neurol. 2005; 4: 866876.
  • 27
    Capuron L,Gumnick JF,Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002; 26: 643652.
  • 28
    Raison CL,Demetrashvill M,Capuron L,Miller AH. Neuropsychiatric adverse effects of interferon-α: recognition and management. CNS Drugs. 2005; 19: 105123.
  • 29
    Meyers CA. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol. 1999; 461: 7581.
  • 30
    Pavol MA,Meyers CA,Rexer JL,Valentine AD,Mattis PJ,Talpaz M. Pattern of neurobehavioral deficits associated with interferon-alpha therapy for leukemia. Neurology. 1995; 45: 947950.
  • 31
    Capuron L,Ravaud A,Dantzer R. Early depressive symptoms in cancer patients receiving interleukin-2 and/or interferon alfa-2b therapy. J Clin Oncol. 2000; 18: 21432151.
  • 32
    Patten SB,Barbui C. Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom. 2004; 73: 207215.
  • 33
    Okereke OI. Neuropsychiatric complications associated with interferon-alpha-2b treatment of malignant melanoma. Psychosomatics. 2002; 43: 237240.
  • 34
    Eggermont AM,Suciu S,MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005; 366: 11891196.
  • 35
    Musselman DL,Lawson DH,Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001; 344: 961966.
  • 36
    Loftis JM,Hauser P. Safety of the treatment of interferon-alpha-induced depression. Psychosomatics. 2003; 44: 524526.
  • 37
    Sonnenblick M,Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest. 1991; 99: 557561.
  • 38
    Feenstra J,Grobbee DE,Remme WJ,Stricker BHC. Drug-induced heart failure. J Am Coll Cardiol. 1999; 33: 11521162.
  • 39
    Khakoo AY,Halushka MK,Rame JE,Rodriguez ER,Kasper EK,Judge DP. Reversible cardiomyopathy caused by administration of interferon alpha. Nat Clin Pract Cardiovasc Med. 2005; 2: 5357.
  • 40
    Klein I,Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001; 344: 501509.
  • 41
    Stuckert JJ,Tarhini AA,Lee S,Sander C,Kirkwood JM. Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-Intergroup phase II trial E2696. J Clin Oncol. 2007; 25(18S): 473S. Abstract 8506.
  • 42
    Vial T,Choquet-Kastylevsky G,Liautard C,Descotes J. Endocrine and neurological adverse effects of the therapeutic interferons. Toxicology. 2000; 142: 161172.
  • 43
    Mofredj A,Howaizi M,Grasset D, et al. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci. 2002; 47: 16491654.
  • 44
    Beuthien W,Mellinghoff HU,Kempis J. Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol. 2005; 24: 507515.
  • 45
    Bachmeyer C,Farge D,Gluckman E,Miclea JM,Aractingi S. Raynaud's phenomenon and digital necrosis induced by interferon-alpha. Br J Dermatol. 1996; 135: 481483.
  • 46
    Johnson DM,Hayat SQ,Burton GV. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma. J Rheumatol. 1999; 26: 10091010.
  • 47
    Kruit WH,Eggermont AM,Stoter G. Interferon-alpha induced Raynaud's syndrome. Ann Oncol. 2000; 11: 15011502.
  • 48
    Al-Zahrani H,Gupta V,Minden MD,Messner HA,Lipton JH. Vascular events associated with alpha interferon therapy. Leuk Lymphoma. 2003; 44: 471475.
  • 49
    Jumbou O,Berthelot JM,French N,Bureau B,Litoux P,Dreno B. Polyarthritis during interferon alpha therapy: 3 cases and review of the literature. Eur J Dermatol. 1995; 5: 581584.
  • 50
    Chan WB,Chow CC,Cockram CS. Interferon alpha treatment and endocrine disease. J R Soc Med. 2003; 96: 481485.
  • 51
    Mandac JC,Chaudhry S,Sherman KE,Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology. 2006; 43: 661672.
  • 52
    Dalgard O,Bjoro K,Hellum K, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med. 2002; 251: 400406.
  • 53
    Koh LK,Greenspan FS,Yeo PP. Interferon-alpha induced thyroid dysfunction: 3 clinical presentations and a review of the literature. Thyroid. 1997; 7: 891896.
  • 54
    Carella C,Mazziotti G,Amato G,Braverman LE,Roti E. Interferon-α-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004; 89: 36563661.
  • 55
    Fleishmann M,Celerier P,Bernard P,Litoux P,Dreno B. Long-term interferon-alpha therapy induces autoantibodies against epidermis. Dermatology. 1996; 192: 5055.
  • 56
    Gutman H,Schachter J,Stopel E,Gutman R,Lahav J. Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy. Cancer. 2002; 94: 780785.
  • 57
    Wong S-F,Jakowatz JG,Taheri R. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma. Ann Pharmacother. 2004; 38: 16551659.
  • 58
    Keung YK,Rizk R,Wu XY,Cobos E. Drug-induced hypertriglyceridemia with and without pancreatitis. South Med J. 1999; 92: 912914.
  • 59
    Willson RA. Visual side effects of pegylated interferon during therapy for chronic hepatitis C infection. J Clin Gastroenterol. 2004; 38: 717722.
  • 60
    Lohmann CP,Kroher G,Bogenrieder T,Spiegel D,Preuner J. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma [letter]. Lancet. 1999; 353: 1326.
  • 61
    Hejny C,Sternberg P,Lawson DH,Greiner K,Aaberg TMJr. Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol. 2001; 131: 782787.
  • 62
    Schering Corporation. Intron A (recombinant interferon alfa-2b for injection). Product information. Kenilworth, NJ: Schering Corporation; 2002.
  • 63
    Egberts F,Lischner S,Russo P,Kampen WU,Hauschild A. Diagnostic and therapeutic procedures for management of melanoma during pregnancy: risk for the fetus? J Dtsch Dermatol Ges. 2006; 4: 717720.
  • 64
    Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, version 3.0. Bethesda, Md: Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services; 2003.
  • 65
    Kirkwood JM,Ibrahim J,Lawson DH, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol. 2001; 19: 14301436.
  • 66
    Gogas H,Ioannovich J,Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354: 709718.
  • 67
    Kleeberg UR,Suciu S,Brocker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer. 2004; 40: 390402.
  • 68
    Cascinelli N,Belli F,MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001; 358: 866869.
  • 69
    Hancock BW,Wheatley K,Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004; 22: 5361.
  • 70
    Grob JJ,Dreno B,de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998; 351: 19051910.
  • 71
    Pehamberger H,Soyer HP,Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998; 16: 14251429.
  • 72
    Creagan ET,Dalton RJ,Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995; 13: 27762783.
  • 73
    Eggermont AM,Suciu S,Santinami M, et al. EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial. Proc Am Soc Clin Oncol. 2007. Abstract 8504.